Regulated cell death in cancer: from pathogenesis to treatment
10.1097/CM9.0000000000002239
- VernacularTitle:Regulated cell death in cancer: from pathogenesis to treatment
- Author:
Linjing GONG
1
;
Dong HUANG
;
Yujun SHI
;
Zong’an LIANG
;
Hong BU
Author Information
1. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
- Keywords:
Anti-cancer therapy;
Apoptosis;
Cancer;
Programmed cell death;
Pyroptosis;
PANoptosis;
Necroptosis;
Ferroptosis;
Diagnosis
- From:
Chinese Medical Journal
2023;136(6):653-665
- CountryChina
- Language:Chinese
-
Abstract:
Regulated cell death (RCD), including apoptosis, pyroptosis, necroptosis, and ferroptosis, is regulated by a series of evolutionarily conserved pathways, and is required for development and tissue homeostasis. Based on previous genetic and biochemical explorations of cell death subroutines, the characteristics of each are generally considered distinctive. However, recent in-depth studies noted the presence of crosstalk between the different forms of RCD; hence, the concept of PANoptosis appeared. Cancer, a complex genetic disease, is characterized by stepwise deregulation of cell apoptosis and proliferation, with significant morbidity and mortality globally. At present, studies on the different RCD pathways, as well as the intricate relationships between different cell death subroutines, mainly focus on infectious diseases, and their roles in cancer remain unclear. As cancers are characterized by dysregulated cell death and inflammatory responses, most current treatment strategies aim to selectively induce cell death via different RCD pathways in cancer cells. In this review, we describe five types of RCD pathways in detail with respect to tumorigenesis and cancer progression. The potential value of some of these key effector molecules in tumor diagnosis and therapeutic response has also been raised. We then review and highlight recent progress in cancer treatment based on PANoptosis and ferroptosis induced by small-molecule compounds, immune checkpoint inhibitors, and nanoparticles. Together, these findings may provide meaningful evidence to fill in the gaps between cancer pathogenesis and RCD pathways to develop better cancer therapeutic strategies.
